Filter Results:
(481)
Show Results For
- All HBS Web (481)
- Faculty Publications (364)
Show Results For
- All HBS Web (481)
- Faculty Publications (364)
Gary P. Pisano
Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details
- September 1999 (Revised September 2005)
- Case
Strategic Deal Making at Millennium Pharmaceuticals
A small start-up in 1993, Millennium Pharmaceuticals was a name-brand biotechnology company by the end of 1998, with a market capitalization of $1.4 billion. The Cambridge-based company's growth strategy had relied heavily on building alliances for early-stage drug... View Details
Keywords: Alliances; Negotiation Deal; Growth and Development Strategy; Pharmaceutical Industry; Cambridge
Watkins, Michael D., and Sarah Matthews. "Strategic Deal Making at Millennium Pharmaceuticals." Harvard Business School Case 800-032, September 1999. (Revised September 2005.)
- December 2012
- Teaching Note
Gene Patents (A) (TN)
By: Richard G. Hamermesh and Matthew Preble
This is the teaching note for case Gene Patents (A). In March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our... View Details
- August 2009 (Revised April 2012)
- Case
Genzyme's CSR Dilemma: How to Play its HAND
By: Christopher A. Bartlett, Tarun Khanna and Prithwiraj Choudhury
Genzyme, a global biotechnology company, launches a program to develop therapies for neglected diseases (e.g., malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets should... View Details
Keywords: Global Strategy; Health Care and Treatment; Intellectual Property; Corporate Social Responsibility and Impact; Partners and Partnerships; Research and Development; Biotechnology Industry
Bartlett, Christopher A., Tarun Khanna, and Prithwiraj Choudhury. "Genzyme's CSR Dilemma: How to Play its HAND." Harvard Business School Case 910-407, August 2009. (Revised April 2012.)
- 2010
- Working Paper
From Bench to Board: Gender Differences in University Scientists' Participation in Commercial Science
This paper examines gender differences in the participation of university life science faculty in commercial science. Based on theory and field interviews, we develop hypotheses regarding how scientists' productivity, co-authorship networks, and institutional... View Details
Keywords: Business Startups; For-Profit Firms; Gender Characteristics; Higher Education; Entrepreneurship; Governing and Advisory Boards; Science-Based Business; Nonprofit Organizations; Biotechnology Industry
Ding, Waverly W., Fiona Murray, and Toby E. Stuart. "From Bench to Board: Gender Differences in University Scientists' Participation in Commercial Science." Harvard Business School Working Paper, No. 11-014, August 2010.
- December 2009 (Revised February 2012)
- Case
Monsanto: Helping Farmers Feed the World
By: David E. Bell, Carin-Isabel Knoop and Mary Shelman
Monsanto has led the effort to bring biotechnology to bear on food production. Through some management missteps and consumer resistance the company had difficulties in its early years. But since Hugh Grant became CEO the picture has brightened with widespread adoption... View Details
Keywords: Food; Global Strategy; Leadership; Production; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; United States
Bell, David E., Carin-Isabel Knoop, and Mary Shelman. "Monsanto: Helping Farmers Feed the World." Harvard Business School Case 510-025, December 2009. (Revised February 2012.)
- April 1993 (Revised November 1994)
- Case
Chiron Corp.
Pablo Valenzuela, vice president of R&D at Chiron Corp., faces several choices for how to allocate scarce resources across several promising projects. These choices will determine Chiron's position in several emerging biotechnology and diagnostic markets, including... View Details
Keywords: Health Testing and Trials; Research and Development; Failure; Business Strategy; Joint Ventures; Strategic Planning; Opportunities; Product Development; Biotechnology Industry; California
Wheelwright, Steven C. "Chiron Corp." Harvard Business School Case 693-052, April 1993. (Revised November 1994.)
- October 2012 (Revised March 2022)
- Case
Kleiner-Perkins and Genentech: When Venture Capital Met Science
By: Felda Hardymon and Tom Nicholas
Genentech is a rare success story in the biotechnology industry. Hundreds of billions of dollars of venture capital have been invested without the expected transformational effects. Established in 1976, Genentech was to develop the new science of recombinant DNA into... View Details
Keywords: Innovation ＆ Entrepreneurship; Venture Capital; Innovation and Invention; Entrepreneurship; Information Technology; Science; Biotechnology Industry; United States
Hardymon, Felda, and Tom Nicholas. "Kleiner-Perkins and Genentech: When Venture Capital Met Science." Harvard Business School Case 813-102, October 2012. (Revised March 2022.)
- Person Page
Press / Media
By: Gary P. Pisano
Thought Leader: Gary Pisano
by Amy Bernstein, strategy+business, Summer 2007
A leading student of the biotech business describes the problems holding the industry back, and how it can overcome... View Details
- April 1993 (Revised May 1994)
- Case
Genzyme Corporation: Strategic Challenges with Ceredase
Genzyme Corp., one of the largest biotechnology companies, has succeeded in developing, manufacturing, and commercializing its first therapeutic, a treatment for a rare genetic disease. Analysis of the case requires students to identify and understand how Genzyme has... View Details
Keywords: Risk Management; Risk and Uncertainty; Corporate Strategy; Technology; Health; Product Development; Biotechnology Industry; Biotechnology Industry; United States
Teisberg, Elizabeth O., and Sharon L. Rossi. "Genzyme Corporation: Strategic Challenges with Ceredase." Harvard Business School Case 793-120, April 1993. (Revised May 1994.)
- October 2016 (Revised September 2017)
- Case
The CRISPR-Cas9 Quarrel
By: Richard G. Hamermesh and Matthew G. Preble
In mid-2016, the Broad Institute and the University of California, Berkeley were in the middle of a contentious patent dispute over which entity controlled a breakthrough gene editing technology called CRISPR-Cas9. With CRISPR-Cas9, scientists might soon be able to... View Details
Keywords: CRISPR; Broad Institute; University Of California Berkeley; Intellectual Property; Patents; Law; Lawsuits and Litigation; Science; Genetics; Entrepreneurship; Biotechnology Industry; United States
Hamermesh, Richard G., and Matthew G. Preble. "The CRISPR-Cas9 Quarrel." Harvard Business School Case 817-020, October 2016. (Revised September 2017.)
- November 2008 (Revised July 2009)
- Background Note
A Managerial Perspective on Clinical Trials
By: Arthur A. Daemmrich
This note describes the history and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Testing and Trials; Product Development; Safety; Biotechnology Industry; Biotechnology Industry
Daemmrich, Arthur A. "A Managerial Perspective on Clinical Trials." Harvard Business School Background Note 709-033, November 2008. (Revised July 2009.)
- January 1996
- Case
Biogen, Inc.: rBeta Interferon Manufacturing Process Development
Biogen, Inc., a Cambridge, MA-based biotechnology company, is wrapping up a project to develop a new manufacturing process for a new drug product that will reposition the company from a purely research-oriented company to a fully integrated pharmaceutical manufacturing... View Details
Keywords: Learning; Technological Innovation; Management Analysis, Tools, and Techniques; Product Development; Organizational Change and Adaptation; Projects; Research and Development; Corporate Strategy; Biotechnology Industry
Wheelwright, Steven C. "Biogen, Inc.: rBeta Interferon Manufacturing Process Development." Harvard Business School Case 696-083, January 1996.
- January 2011 (Revised January 2012)
- Supplement
The Case of the Unidentified Healthcare Companies2010 (CW)
By: Richard M.J. Bohmer, Ethan S Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected rations for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
- February 2006 (Revised August 2006)
- Case
deCODE Genetics: Hunting for Genes to Develop Drugs
By: Debora L. Spar
In 1996, Kari Stefansson launched a new kind of biotechnology company and a whole new way of attacking diseases. Based in Iceland, his firm, deCODE Genetics, plans to identify the individual genetic markers that lead to society's most prevalent diseases. To do so, it... View Details
Keywords: Information; Innovation Strategy; Genetics; Ethics; Health Disorders; Biotechnology Industry; Iceland
Spar, Debora L., and Chris Bebenek. "deCODE Genetics: Hunting for Genes to Develop Drugs." Harvard Business School Case 706-040, February 2006. (Revised August 2006.)
- November 2003 (Revised December 2003)
- Case
Proteome Systems Limited: The First Five Years
A Sydney-based biotechnology company is moving from the development of proteomics technology to the commercialization of its first instruments in the worldwide proteomics market. The case study highlights the range of activities engaged in by the 120-person company,... View Details
Keywords: Organizational Change and Adaptation; Information Technology; Commercialization; Entrepreneurship; Biotechnology Industry; Sydney
West, Jonathan, and Mona Ashiya. "Proteome Systems Limited: The First Five Years." Harvard Business School Case 604-049, November 2003. (Revised December 2003.)
- 25 Mar 2016
- HBS Seminar
Curtis Keith, Harvard University, Blavatnik Biomedical Accelerator
- January 2011 (Revised January 2012)
- Case
The Case of the Unidentified Healthcare Companies2010
By: Richard Bohmer, Ethan Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected ratios for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
Bohmer, Richard, Ethan Bernstein, Margarita Krivitski, and Srinidhi Reddy. "The Case of the Unidentified Healthcare Companies2010." Harvard Business School Case 611-043, January 2011. (Revised January 2012.)
- Article
Network Effects in the Governance of Strategic Alliances
We argue that the stock of prior alliances between participants in the biotechnology sector forms a network that serves as a governance mechanism in interfirm transactions. To test how this network substitutes for other governance mechanisms, we examine how equity... View Details
Keywords: Network Effects; Governance; Strategy; Alliances; Stocks; Market Transactions; Equity; Mortgages; Biotechnology Industry
Robinson, David, and Toby E. Stuart. "Network Effects in the Governance of Strategic Alliances." Journal of Law, Economics & Organization 23, no. 1 (April 2007): 242–273.
- February 2010
- Case
Amyris Biotechnologies: Commercializing Biofuel
By: Gary P. Pisano and Alison Berkley Wagonfeld
In 2009, Amyris Biotechnologies was building a plant in Brazil that used synthetic biology to convert sugarcane into both renewable fuels and renewable chemicals. The Amyris' marketing team was investigating the commercial interest for both types of products, while the... View Details
Keywords: Renewable Energy; Chemicals; Risk Management; Product Marketing; Product Development; Production; Environmental Sustainability; Commercialization; Biotechnology Industry; Brazil
Pisano, Gary P., and Alison Berkley Wagonfeld. "Amyris Biotechnologies: Commercializing Biofuel." Harvard Business School Case 610-031, February 2010.